Chen Bin, Pan Wenyan, Lin Xiaoxi, Hu Zhenzhen, Jin Yunbo, Chen Hui, Ma Gang, Qiu Yajing, Chang Lei, Hua Chen, Zou Yun, Gao Yang, Ying Hanru, Lv Dongze
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhizaoju Road, Shanghai, 200011, China.
Department of Plastic and Reconstructive Surgery, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Tumour Biol. 2016 Feb;37(2):2765-71. doi: 10.1007/s13277-015-4046-2. Epub 2015 Sep 26.
Cutaneous squamous cell carcinoma (cSCC) is an epidermal keratinocyte-derived skin tumor, which is the second most common skin cancer in the general population. Recently, studies showed that microRNAs (miRNAs) played an important role in the development of cancer. In our study, we showed that the expression of SRCIN1 was lower in cSCC tissues than in the matched normal tissues. Moreover, there was significant inversed correlation between miR-346 and SRCIN1 in cSCC tissues. The luciferase reporter assay data showed that miR-346 can target the SRCIN1 message via the 3'-untranslated region (UTR) of SRCIN1. Overexpression of miR-346 inhibited the messenger RNA (mRNA) and protein expression of SRCIN1 in the A431 cells. In addition, ectopic expression of miR-346 promoted the A431 cell proliferation and migration. Meanwhile, SRCIN1 overexpression inhibited the A431 cell proliferation and migration. Rescue experiment has showed that SRCIN1 overexpression reduced the miR-346-induced A431 cell proliferation and migration. Herein, this study may provide miR-346 as a new therapeutic target for cSCC.
皮肤鳞状细胞癌(cSCC)是一种源自表皮角质形成细胞的皮肤肿瘤,是普通人群中第二常见的皮肤癌。最近,研究表明微小RNA(miRNA)在癌症发展中起重要作用。在我们的研究中,我们发现cSCC组织中SRCIN1的表达低于配对的正常组织。此外,cSCC组织中miR-346与SRCIN1之间存在显著的负相关。荧光素酶报告基因检测数据表明,miR-346可通过SRCIN1的3'-非翻译区(UTR)靶向SRCIN1信使RNA。miR-346的过表达抑制了A431细胞中SRCIN1的信使核糖核酸(mRNA)和蛋白质表达。此外,miR-346的异位表达促进了A431细胞的增殖和迁移。同时,SRCIN1的过表达抑制了A431细胞的增殖和迁移。挽救实验表明,SRCIN1的过表达降低了miR-346诱导的A431细胞增殖和迁移。在此,本研究可能为cSCC提供miR-346作为新的治疗靶点。